BHCM
IMMX icon

Brevan Howard Capital Management’s Immix Biopharma IMMX Stock Holding History

Brevan Howard Capital Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57,508
Closed -$524K – 2302
2026
Q1 		$524K Buy
+57,508
New +$422K ﹤0.01% 1282

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Brevan Howard Capital Management's IMMX Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Immix Biopharma (IMMX) in Q2 2026, closing a stake of 57,508 shares — an estimated $524K sold.

Brevan Howard Capital Management first reported a position in IMMX in Q1 2026 and held it in 1 quarter. The position peaked at $524K in Q1 2026. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Immix Biopharma position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 57,508 Immix Biopharma shares in Q2 2026, an estimated $524K.
  • Brevan Howard Capital Management first reported a position in Immix Biopharma in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Immix Biopharma position peaked at $524K in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.